-
Taxonomy & unit
-
us-gaap: USD/shares
-
Description
-
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
-
Summary
-
Tcr2 Therapeutics Inc. quarterly/annual Earnings Per Share, Diluted history and growth rate from Q2 2021 to Q1 2023.
- Tcr2 Therapeutics Inc. Earnings Per Share, Diluted for the quarter ending March 31, 2023 was -1.03 USD/shares, a 35.5% decline year-over-year.
- Tcr2 Therapeutics Inc. Earnings Per Share, Diluted for the twelve months ending March 31, 2023 was -4.2 USD/shares.
- Tcr2 Therapeutics Inc. annual Earnings Per Share, Diluted for 2022 was -3.93 USD/shares, a 49.4% decline from 2021.
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Quarterly (USD/shares)
Earnings Per Share, Diluted, YoY Quarterly Growth (%)